Ginestier C, Adélaïde J, Gonçalvès A, Repellini L, Sircoulomb F, Letessier A, Finetti P, Geneix J, Charafe-Jauffret E, Bertucci F, Jacquemier J, Viens P, Birnbaum D
UMR599 Inserm, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Département d'Oncologie Moléculaire, Marseille, France.
Oncogene. 2007 Nov 1;26(50):7163-9. doi: 10.1038/sj.onc.1210528. Epub 2007 May 21.
Breast cancers that overexpress the ERBB2 tyrosine kinase receptor may be treated with the recombinant humanized monoclonal anti-ERBB2 antibody trastuzumab (herceptin). However, resistance to this targeted therapy is frequent. We have determined the response of 18 breast tumor cell lines to trastuzumab and compared it with the ERBB2 phosphorylation status using antibodies directed against tyrosine residue 1248. We show that sensitivity to trastuzumab is frequently associated with the expression of a phosphorylated ERBB2 protein.
过表达ERBB2酪氨酸激酶受体的乳腺癌可用重组人源化抗ERBB2单克隆抗体曲妥珠单抗（赫赛汀）进行治疗。然而，这种靶向治疗常常会产生耐药性。我们测定了18种乳腺肿瘤细胞系对曲妥珠单抗的反应，并使用针对酪氨酸残基1248的抗体将其与ERBB2磷酸化状态进行了比较。我们发现，对曲妥珠单抗的敏感性常常与磷酸化ERBB2蛋白的表达相关。
